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The Nuclear factor-2 erythroid related factor-2 (Nrf2) is a redox regulated transcription factor involved in
the regulation of antioxidant defence systems. It drives the production of endogenous antioxidant
defences and detoxifying enzymes. Nuclear factor-kappa light chain enhancer of B cells (NF-κB) is a
transcription factor, involved in proinﬂammatory cytokine production, in addition to its immunological
function. Both Nrf2 and NF-κB regulation are co-ordinated in order to maintain redox homeostasis in
healthy cells. However, during pathological conditions this regulation is perturbed offering an
opportunity for therapeutic intervention. Diabetic neuropathy is a condition, in which change in
expression pattern of Nrf2 and NF-κB has been reported. This review aims to focus on the role of the
Nrf2 and NF-κB in diabetic neuropathy and summarizes the therapeutic outcomes of various pharma-
cological modulators targeted at the Nrf2–NF-κB axis in diabetic neuropathy.
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Diabetes is one of the most debilitating conditions in patients
affecting a substantial proportion of the world's population. Diabetes
can predispose an individual to metabolic, cardiovascular distur-
bances and obesity, and these pathologies are accompanied by
vascular complications [1]. Hyperglycaemia-induced damage to the
endothelial cells results in micro-vascular complications of the
diabetes such as diabetic neuropathy, nephropathy and retinopathy
and macro-vascular complications such as cardiomyopathy [2]. Dia-
betic neuropathy remains the most severe form of complication
affecting 40–50% of people with both types of diabetes. The clinicalB.V.
+91 40 23073751.
iper@gmail.com (A. Kumar).
Open access under CC BY license.features of diabetic neuropathy range from sensory deﬁcit to allody-
nia and hyperalgesia. Diabetic neuropathy arises from the long term
effects of hyperglycaemia induced damage to peripheral nervous
tissue as well as the vasa nervorum [3].
The current knowledge of pathophysiological mechanisms of
hyperglycaemia-induced diabetic neuropathy is substantial and
recent advances made in ﬁeld could lead to the development of
some novel therapeutic strategies targeted at advance glycation
end products (AGE), sorbitol accumulation, protein kinase C (PKC)
activation and hexosamine pathway. The axis of pathophysiological
factors responsible for diabetes and diabetic neuropathy converge at
two of the most extensively studied pathways, oxidative–nitrosative
stress and neuroinﬂammation (Fig. 1). Molecular studies have revealed
the involvement of transcriptional regulators such as Nrf2-Keap1 and
the NF-κB inﬂammatory cascade in the pathophysiology of many
diseases [4].
NF-κB has been shown to respond to the cellular redox status
since a reducing environment prevents its activation whereas 
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Fig. 1. Possible factors in the pathophysiology of diabetic neuropathy. Hyperglycaemia induces excess formation of sorbitol through polyol pathway, advanced glycation end
products (AGE), mitochondrial dysfunction and causes mitogen activated protein kinases (MAPK), poly ADP ribosyl polymerase (PARP) and protein kinase C (PKC) hyper-
activation [7]. All these pathways can contribute to nitrosative/oxidative stress in neuronal cells and endothelial cells of the vasa nervorum through depletion of endogenous
antioxidant defences and excess generation of reactive oxygen species (ROS). The resulting oxidative stress leads to the activation of redox regulated transcription factors
such as nuclear factor erythroid 2 related factor-2 (Nrf2), nuclear factor kappa light chain enhancer of B cells (NF-κB). Although Nrf2 is transiently activated by oxidative
stress, the hyperglycaemic stress induced extracellular related kinase (ERK) activation restrain continued Nrf2 activation [8]. A decline in Nrf2 activity and a persistent
increase in NF-κB activity can lead to neuroinﬂammation and increased nitrosative–oxidative stress. These further lead to cumulative damage to peripheral nerve ﬁbres,
impaired blood supply to neuronal tissue [9], release of algogens like bradykinins and prostaglandins, which cause hypersensitivity to pain and hence, result in the
development of neuropathic pain [10]. Oxidative and nitrosative stress can also lead to massive DNA damage, which is a strong stimulator of PARP, hence causes neuronal
apoptosis. All these events will culminate in the development of diabetic neuropathy (DN).
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Fig. 2. Role of NF-κB and Nrf2 in diabetic neuropathy. Hyperglycaemia induced imbalance in Nrf2–NF-κB regulation can contribute to the pathogenesis of diabetic
neuropathy. Enhanced NF-κB activity during the hyperglycaemic state is associated with excess production of proinﬂammatory cytokines such as IL-6, TNF-α, COX-2 and
iNOS. These proteins and enzymes are prerequisite mediators for the initiation and ampliﬁcation of inﬂammatory processes in neuronal cells [9]. Reduced Nrf2 activity
results in impaired antioxidant defence and is characterized by decline in superoxide dismutase (SOD), catalase and glutathione (GSH) levels. Additionally, it decreases the
production of detoxifying enzymes such as, haem-oxygenase-1 (HO-I) and NADPH quinone oxidoreductase (NQO1), leading to nitrosative and oxidative stress [14].
Neuroinﬂammation due to elevated NF-κB can also activate microglia and astrocytes, which further augments the release of proinﬂammatory mediators, thus develops a
vicious cycle of inﬂammation. Release of algogenic mediators, such as prostaglandins, bradykinins and chemokines due to neuroinﬂammation, can sensitise the nerve ﬁbres
to painful stimulus and end up in sensorimotor alterations [10]. NF-κB mediated neuroinﬂammation can also result in endoneurial hypoxia due to decreased blood supply to
the nervous tissue and ganglion [9]. This neuronal hypoxic condition leads to dysfunction of mitochondrial electron transport chain (etc), decreased efﬁciency of
mitochondria, and results in increased ROS production. Nitrosative and oxidative stress generated in the nerve cells can also lead to increased AGE formation and protein
kinase C (PKC) activation [7] and increased peroxynitrite mediated PARP over-activation and apoptosis. The manifestations of neuroinﬂammation and oxidative stress can
cumulatively cause the structural damage which can lead to the functional, sensorimotor and biochemical deﬁcits which are characteristic of diabetic neuropathy.
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dation of IκB [5]. Nrf2 increases intracellular GSH levels and
GSH-dependent enzymes favouring a reducing environment therebyinhibiting NF-κB. Li et al. demonstrated that Nrf2-deﬁcient mice
exhibit greater induction of pro-inﬂammatory genes regulated by
NF-κB such as interleukins, TNF-α, iNOS and COX-2 pointing
Fig. 3. Crosstalk between the Nrf2 and NF-κB pathways. Oxidative stress mediated Nrf2 activation can lead to the production of antioxidant enzymes and cytoprotective
enzymes such as SOD, catalase, GSH, haem-oxygenase-1 (HO-1) and NADPH quinone oxidoreductase (NQO1) and increased synthesis of GSH, NADPH and multidrug
transporters. Nrf2 bind to the antioxidant response element (ARE) on DNA and maintains redox balance in body [14]. Normally Nrf2 is bound to cytosolic repressor Kelch-like
ECH-associated protein 1 (Keap1) and labelled for polyubiquitination mediated proteasomal degradation. However, during oxidative insult, the sulfhydryl groups on Keap1
are oxidised, causing the alteration in conﬁrmation of Keap1, and hence releases Nrf2, which then binds with ARE elements of the genome along with small Maf proteins
[14,15]. NF-κB is another redox regulated transcription factor, involved in inﬂammation, immune function, cellular growth and apoptosis [16]. p65 is a Rel protein with
transactivation efﬁciency whereas its partner p50 does not possess transcriptional activity. Oxidative stress can cause the activation of IκB kinase (IKK). Activation of IKK
causes phosphorylation of inhibitor of NF-κB, IκB and hence targets the later for polyubiquitination mediated proteasomal degradation, results in release of NF-κB, which
then migrates into the nucleus, binds with the κ region of genome. With the help of other coactivators and histone acetyl transferases (HAT), NF-κB causes the transcription
of proinﬂammatory mediators such as interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), cyclooxygenase-2 (COX-2), interleukin-1 (IL-1), intracellular adhesion molecule
(ICAM) and inducible nitric oxide synthase (iNOS) [16]. Further these two pathways are proposed to inhibit each other at their transcription level via protein–protein
interactions or through secondary messenger effects. Nrf2 pathway inhibits the activation of NF-κB pathway by increasing antioxidant defences and HO-1 expression, which
efﬁciently neutralizes ROS and detoxify toxic chemicals and hence, reduces ROS mediated NF-κB activation [11]. Nrf2 pathway also inhibits NF-κB mediated transcription by
preventing the degradation of IκB-α. Similarly, NF-κB mediated transcription reduces the Nrf2 activation by reducing the ARE gene transcription, decreases free CREB binding
protein (CBP) by competing with Nrf2 for CH1-KIX domain of CBP [12]. NF-κB also enhances the recruitment of histone deacetylase3 (HDAC3) to the ARE region by binding to
Mafk and hence interferes with the transcriptional facilitation of Nrf2 [15].
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pro-inﬂammatory reactions [6]. Soares et al. showed that HO-1
inhibited the TNF-α dependent activation of NF-κB in endothelial
cells. It has been postulated that HO-1 induced by the Nrf2-EpRE
interaction inhibits the NF-κB dependent transcriptional appara-
tus. Inhibition of NF-κB downstream of IκB phosphorylation/
degradation and nuclear translocation has been hypothesized to
be the site of action of HO-1 [11]. These data further support the
concept that the Nrf2 directed increase in the expression of
HO-1 is one of the hubs for cross-talk between Nrf2 and NF-κB
(Figs. 2 and 3).
Recent studies have shown that NF-κB suppresses the tran-
scriptional activity of Nrf2. Liu et al. demonstrated that NF-κB p65
subunit repressed the beneﬁcial effects of Nrf2 by promoting the
localisation of transcription repressors, histone deacetylases with
Nrf2/ARE and sequestering coactivators like CREB binding protein
(CBP) [12]. Cells over-expressing NF-κB showed lesser expression
of HO-1 which further conﬁrms that NF-κB activation can act as a
repressor of Nrf2 transcriptional activity. In a recent study,
Yu et al. found that the N-terminal region of p65 subunit of NF-
κB was physically associated with Keap1, and thus provide an
additional mechanism for Nrf2–ARE inhibition. It was also sug-
gested that NF-κB not only interacted with cytosolic Keap1 but
also promoted nuclear translocation of Keap1 [13].Previous studies with agents like curcumin [17], melatonin [18],
resveratrol [19] and sulphoraphane [20] have reported beneﬁcial
effects in ameliorating various functional (motor nerve conduction
velocity and nerve blood ﬂow), sensorimotor (thermal and
mechanical hyperalgesia) and biochemical deﬁcits in experimental
diabetic neuropathy (Fig. 4). These agents also suppressed the
increased activity and levels of NF-κB and associated proteins and
hence protected against neuroinﬂammation in diabetic neuropa-
thy. As expected, treatment with these agents increased the levels
of Nrf2 and HO-1 which further modulating the redox regulation
of pro-inﬂammatory signalling pathways. Additional studies to
ﬁnd any common co-activators or co-repressors shared by these
transcription factors and co-regulation by upstream and down-
stream signalling in these cascades will enable a better apprecia-
tion of the crosstalk between these two transcription factors in
diabetic neuropathy.
In summary, Nrf2 and NF-κB individually affect many signalling
cascades to maintain a redox homeostasis; additionally they
interact with each other to further modulate level of key redox
modulators in health and disease. Studies with speciﬁc agents that
might regulate the crosstalk between the two central pleiotropic
transcription factors, Nrf2 and NF-κB, may be one of the prospec-
tive strategies that might aid in ﬁnding newer therapeutic choices
for prevention and treatment of diabetic neuropathy.
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Fig. 4. Imbalance of Nrf2–NF-κB in diabetic neuropathy and effects of simultaneous-targeting Nrf2–NF-kB pathway using pharmacological agents. Hyperglycaemia induced
disturbances in Nrf2–NF-κB axis can contribute to the development of several diabetic vascular complications such as neuropathy, nephropathy and retinopathy. Enhanced
NF-κB activity in diabetic neuropathy leads to the development of neuroinﬂammation, production of proinﬂammatory cytokines, nerve damage, impaired motor nerve
conduction velocity (MNCV) due to demyelination, impaired neuronal blood ﬂow (NBF) and production of algogenic mediators and hence causes pain hypersensitivity.
Reduced Nrf2 activity is associated with enhanced oxidative stress in the neurons, which leads to the activation of PARP mediated neuronal apoptosis, AGE formation, PKC
activation and allodynia and hyperalgesia due to the damage to the sensory ﬁbres. However, this disturbed balance can be modulated pharmacologically to attenuate various
deﬁcits in diabetic neuropathy. The pharmacological modulation of NF-κB–Nrf2 axis by some pharmacological agents like Curcumin [17], Melatonin [18], Resveratrol[19] and
Sulforaphane [20] produced beneﬁcial effect by inhibiting NF-κB and activating Nrf2. The experimental outcomes of the studies of above mentioned compounds in
streptozotocin (STZ) induced diabetic neuropathy model are manifested in the form of improved MNCV and NBF, decreased lipid peroxidation, IL-6, TNF-α levels, decreased
expression of COX-2 and iNOS and reduced apoptosis.
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